Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,067 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: yamaguchi m. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y. Toyokawa G, et al. Among authors: yamaguchi m. Int J Clin Oncol. 2014 Aug;19(4):601-6. doi: 10.1007/s10147-013-0619-5. Epub 2013 Oct 26. Int J Clin Oncol. 2014. PMID: 24158772
Impact of the epidermal growth factor receptor mutation status on the post-recurrence survival of patients with surgically resected non-small-cell lung cancer.
Takenaka T, Takenoyama M, Yamaguchi M, Toyozawa R, Inamasu E, Kojo M, Toyokawa G, Yoshida T, Shiraishi Y, Morodomi Y, Hirai F, Taguchi K, Shimokawa M, Seto T, Ichinose Y. Takenaka T, et al. Among authors: yamaguchi m. Eur J Cardiothorac Surg. 2015 Mar;47(3):550-5. doi: 10.1093/ejcts/ezu227. Epub 2014 Jun 3. Eur J Cardiothorac Surg. 2015. PMID: 24894095
Predictive and prognostic impact of primary tumor-bearing lobe in nonsmall cell lung cancer patients treated with anti-PD-1 therapy.
Takamori S, Takada K, Shimokawa M, Matsubara T, Haratake N, Miura N, Toyozawa R, Yamaguchi M, Takenoyama M, Yoneshima Y, Tanaka K, Okamoto I, Tagawa T, Mori M. Takamori S, et al. Among authors: yamaguchi m. Int J Cancer. 2020 Oct 15;147(8):2327-2334. doi: 10.1002/ijc.33030. Epub 2020 May 18. Int J Cancer. 2020. PMID: 32356560
Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Takamori S, Takada K, Shimokawa M, Matsubara T, Fujishita T, Ito K, Toyozawa R, Yamaguchi M, Okamoto T, Yoneshima Y, Tanaka K, Okamoto I, Tagawa T, Mori M. Takamori S, et al. Among authors: yamaguchi m. Lung Cancer. 2021 Feb;152:27-33. doi: 10.1016/j.lungcan.2020.11.026. Epub 2020 Dec 4. Lung Cancer. 2021. PMID: 33341085
6,067 results